Related references
Note: Only part of the references are listed.First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al.
LANCET (2021)
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas
Robin Guo et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S. Popat et al.
ANNALS OF ONCOLOGY (2020)
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma (vol 37, 340-353.e1-e6, 2020)
Beatriz Salvador-Barbero et al.
CANCER CELL (2020)
The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton et al.
NATURE (2020)
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Verena Wagner et al.
ONCOGENE (2020)
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
Raffit Hassan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
High Time for Complete Ban on Asbestos Use in Developing Countries
Tianhui Chen et al.
JAMA ONCOLOGY (2019)
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations
Marjorie G. Zauderer et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
Shatha AbuHammad et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
Vasiliki Panou et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Marcus Ruscetti et al.
SCIENCE (2018)
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Jutija Hmeljaki et al.
CANCER DISCOVERY (2018)
BTS guideline for the investigation and management of malignant pleural mesothelioma
Ian Woolhouse et al.
BMJ OPEN RESPIRATORY RESEARCH (2018)
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
Julien Bollard et al.
GUT (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells
Mara A. Bonelli et al.
NEOPLASIA (2017)
Targeting CDK4 and CDK6: From Discovery to Therapy
Charles J. Sherr et al.
CANCER DISCOVERY (2016)
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing
Marieke Hylebos et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno et al.
NATURE GENETICS (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts
Chiara Ambrogio et al.
CANCER RESEARCH (2014)
Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Ernest Nadal et al.
CLINICAL CANCER RESEARCH (2013)
Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery
Marco Bezzi et al.
GENES & DEVELOPMENT (2013)
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008
Vanya Delgermaa et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2011)
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa et al.
NATURE GENETICS (2011)
Downregulation of Bcl-x(L) and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy
Emilie Varin et al.
CARCINOGENESIS (2010)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
Sanja Dacic et al.
VIRCHOWS ARCHIV (2008)
Cellular senescence: when bad things happen to good cells
Judith Campisi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Global gene expression profiling of pleural mesotheliomas:: Overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction
F López-Ríos et al.
CANCER RESEARCH (2006)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
